Biomarkers · Inflammation
Immunoglobulin G (IgG)
The published study could not tell whether risk rises or falls: its 95% interval includes no change. No risk curve catalogued yet.
Published risk of death1.03×per 1 SD increase in IgG (95% CI 0.94–1.14) · Meta-analysis of Augsburg MONICA/KORA, MONICA Glasgow, Speedwell and one other published study with baseline Ig levels (n=8218)
What studies found when this marker was changed
They describe what happened in those study groups, not a recommendation. See all catalogued interventions.
Measured changes in IgG, study by study
1 effect with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Study results in the groups studied, not predictions for a person.
| Type | Intervention | Reported effect | Evidence | Source |
|---|---|---|---|---|
| pharmacologic | Repeated intravenous infusions of the FcRn antagonist efgartigimod (first-in-human ascending-dose study) in healthy volunteers | Multiple dosing lowered total serum IgG by an average of 75% of baseline (single dose up to 50%); IgG returned to baseline ~8 weeks after the last dose | RCT | Ulrichts P, Guglietta A, Dreier T, et al. Neonatal Fc receptor antagonist… |